RESUMO
ObjectiveTo investigate the clinical effect of carvedilol in the treatment of chronic heart failure patients with arrhythmia.Methods120 cases of hospitalized cases of cardiology were randomly divided into treatment and control groups by checking the random number table.The control group was given benazepril hydrochloride combined digoxin cardiac medicine and furosemide or hydrochlorothiazide,spironolactone and other diuretics in the treatment.The treatment group was given carvedilol based on the treatment of the control group.Followed up for 12 weeks,the clinical manifestations,blood pressure and heart rate,left ventricular ejection fraction(EF) and arrhythmias before and after treatment were obsered,and to determine the efficacy.ResultsThe treatment group decreased heart rate,corrected ventricular premature contraction,ventricular contraction and ventricular tachycardia in comparison with the control group with significant differences(t =6.018、5.319、7.623、6.194、7.562,all P ＜0.001 ),and there was a significantly statistical significance( P ＜ 0.01 ) that the treatment group can increase the ejection fraction compared with the control group.The markedly and total efficiency was more effective in the treatment group than the control group,which was statistically significant(x2 =34.301,P ＜0.05).ConclusionThere was a positive effect of carvedilol in improving heart function,reduceing arrhythmias and mortality,and reducing hospitalization rate and other aspects.
RESUMO
ObjectiveTo study the value of serum soluble intercellular adhesion molecule-1 (sICAM-1),B-type natriuretic peptide (BNP) and C-reactive protein (CRP) levels detection on assessment of illness in patients with congestive heart failure.MethodsSixty-three patients with congestive heart failure were involved in this study.The levels of serum sICAM-1,BNP and CRP were compared in patients with different NYHA cardiac function classification before and after treatment.ResultsThe levels of serum sICAM-1,BNP and CRP in NYHA cardiac function classification ≥ Ⅲ grade patients were significantly higher than those in NYHA cardiac function classification ＜ Ⅲ grade patients[ (392.6 ± 73.3) μ g/L vs.(212.6 ± 83.4) μ g/L,( 1992.5 ±1173.7) ng/L vs.(512.6 ± 283.2) ng/L,(49.3 ± 33.5 ) mg/L vs.(6.1 ± 3.6) mg/L] (P ＜ 0.01 ).The levels of serum sICAM-1,BNP and CRP after treatment were significantly decreased compared with those before treatment [ ( 168.9 ± 52.5) μ g/L vs.(362.8 ± 123.1 ) μ g/L,(68.6 ± 38.4) ng/L vs.(1470.9± 1460.1) ng/L,(3.6±2.8) mg/L vs.(34.1 ±29.8) mg/L] (P ＜ 0.01).Conclusion Serum sICAM-1,BNP and CRP levels are positively related with illness,and serum sICAM-1,BNP and CRP levels may be judged as an index assessing treatment effect and prognosis.
RESUMO
Paeonol is an nerb which has been used us an anodyne. The analgesic action of Paeonol has been shown in this paper by using the following methods: Mice licking hind paw on hot plate (55℃); mice wring evoked by ip 0. 7% acetic acid 10 ml ? kg-1; continuous pain stimuli elicited by sc 2. 5% formaldehyde 0. 03 ml in fore paw of mice.No tolerance of analgesic effect was found after daily sc of Paeonol 100 mg ? kg-1for 7 d in mice assayed with hot plate method. In naloxone-challenge test, no jumping response was observed in mice treated with Paeonol 690mg ? kg-1, the maximal tolerance dose. The results indicate that Paeonol induced no morphine-like tolerance norphysical dependence.The analgesic action of Paeonol was not an-tagonizd by naloxone, but was eliminated by in-traperitoneal injection reserpine 3 mg ? kg-1 3 h prior to Paeonol. These results demonstrate that Paeonol belongs to the non-narcotic analgesic, and suggested that the analgesic action of Paeonol may be related to the monoamine level in brain.